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Coronary Plaque Neovascularization and Hemorrhage
A Potential Target for Plaque Stabilization?*
Aloke V. Finn, MD,† Rakesh K. Jain, PHD‡
Atlanta, Georgia; and Boston, MassachusettsAngiogenesis, or the growth of new blood vessels from
existing host vessels, is increasingly being recognized
as important in the growth and progression of athero-
sclerosis, the primary cause of coronary artery and
cerebrovascular disease. Neovascularization of athero-
sclerotic plaques was first noted by Koester (1) in
1876. Later Barger et al. (2) proposed that the growth
and extension of adventitial blood vessels called vasa
vasorum (VV) into the intima occurs as a response to
See page 32
tissue hypoxia, which occurs when the intima thick-
ens beyond the diffusion limits of oxygen and
nutrients (approximately 350 M) (3). Indeed,
increases in hypoxia-inducible factor alpha, a tran-
scription factor that is up-regulated under hypoxic
conditions and promotes hypoxia-dependent neo-
vascularization, have been found in human athero-
sclerotic plaques (4).
Because many of the VV that grow into the plaque
are immature (i.e., they lack mural cells and compe-
tent endothelial cell [EC] junctions), they are inher-
ently leaky, permitting inflammatory cell infiltration
and influx of blood constituents, especially erythro-
cytes, into the plaque. Most of the intraplaque vessels
are endothelialized, but only a few possess mural
pericytes and smooth muscle cells (5,6). The lack of
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Enlight Biosciences.mural cells and poorly formed EC junctions contrib-
ute to the incompetence of immature intraplaque VV.
Erythrocyte membranes, rich in phospholipids and
free cholesterol, and free hemoglobin, a source of
oxidative damage and reactive oxygen species, contrib-
ute significantly to necrotic core expansion and in-
flammatory cell infiltration, 2 features essential to all
high-risk plaques (7).
Neovessels also promote the entry of leukocytes
into the plaque by up-regulation of adhesion mole-
cules, such as intercellular adhesion molecule-1, vas-
cular cell adhesion molecule-1, and E-selectin (8).
Increased matrix metalloproteinase release from acti-
vated macrophages and proteases secreted from mast
cells cause further damage to microvessels and facili-
tate intraplaque hemorrhage (9).
In this issue of iJACC, work by Gössl et al. (10)
lends further support to the concept that coronary
VV neovascularization plays an important role in
plaque progression through promotion of in-
traplaque hemorrhage. Using hearts from 15 pa-
tients obtained by autopsy, they demonstrated that
VV density was higher in nonstenotic (defined as
50% lumen diameter stenosis) and noncalcified
plaques compared with normal segments. As ex-
pected, the amount of iron and glycophorin A (an
anion-exchange protein specific to erythrocytes)
was significantly higher in nonstenotic and stenotic
plaques compared with normal segments and cor-
related with VV density.
Perhaps more novel and interesting is their finding
that in calcified stenotic plaques, VV spatial density
was lowest; however, relatively high amounts of gly-
cophorin A and iron were found in these lesions,
suggesting that intraplaque hemorrhage is associated
with plaque calcification.
These findings confirm earlier work linking hem-
orrhage to coronary plaque progression. In a relatively
large number of human coronary plaques from victims
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42f sudden coronary death, Kolodgie et al. (11) dem-
nstrated that there was a greater frequency of previ-
us intraplaque hemorrhages in coronary atheroscle-
otic lesions prone to rupture compared with early
esion morphologies or stable plaques. Importantly,
he extent of intraplaque hemorrhage corresponded to
he size of the necrotic core, suggesting that deposi-
ion of red cell membranes—rich in free cholesterol
nd phospholipids—is an important cause of core
xpansion and plaque progression. Although addi-
ional information about the type of plaque morphol-
gy included in the nonstenotic plaque group would
ave strengthened the study of Gössl et al. (10) by
nhancing our understanding of how neovasculariza-
ion and hemorrhage contribute to plaque progres-
ion, quantitation of VV density using micro-
omputed tomography (CT) images represents a
ignificantly novel aspect of this study. Prior quanti-
ation of VV density histologically has also been
hown to correlate with plaque progression and rein-
orces the authors’ conclusions (12).
The association of intraplaque hemorrhage with
laque calcification is a more novel aspect of this
tudy. Although coronary artery calcification correlates
ith the severity and extent of coronary disease at
utopsy (13), there does not appear to be a linear
elationship between coronary calcium and risk for
uture coronary events (14). Pathologically, ruptured
laques do demonstrate significantly higher calcium
evels than do thin cap fibroatheromas (i.e., vulnerable
laques), but the causes for this remain unknown (15).
his same relationship holds true for mean number of
V and for hemosiderin-laden macrophages (another
ign of previous hemorrhage) (12); therefore, it is
empting to speculate that increases in coronary cal-
ium levels seen in ruptured plaque may result from
emorrhage. However, neither study demonstrates a
ause and effect phenomenon, which is essential to
urthering our understanding of the relationship of
oronary calcification and plaque stabilization. In-
tead, it begs the question of how and why heavy
alcification occurs in human coronary atherosclerotic
isease and whether it is simply a healing response to
emorrhage.
Although not specifically addressed in this study,
nother important and related question involves un-
erstanding how and why hemorrhage occurs in
uman coronary atherosclerotic lesions. Recently,
luimer et al. (6) demonstrated abnormalities such
s incomplete endothelial junctions and basement
embrane detachment in human intraplaque ECs.
n addition, there was monocyte and mast cell
ccumulation in these areas, substantiating the con- tept that intraplaque microvessels are abnormal and
hus provide entry points for erythrocyte and other
lood cell components into the plaque. However,
o change in mural cell coverage was observed from
arly, advanced, and ruptured coronary plaques,
uggesting lack of mural cell coverage alone may not
e responsible for intraplaque hemorrhage. This
aradigm, that pathologic angiogenesis within
laques leads to hemorrhage, would be strength-
ned by in vivo imaging data.
Further work needs to be done to understand
recisely how and which molecules regulate the key
ro-angiogenic and antiangiogenic factors in the VV
ithin the plaques that show hemorrhage. The mech-
nisms responsible for the abnormal EC morphology
een in intraplaque vessels undoubtedly involve vascu-
ar endothelial growth factor (VEGF). Angiogenesis
epends on EC invasion and proliferation as well as
ericyte coverage of vascular sprouts, processes that are
oordinated by VEGF and platelet-derived growth
actor (PDGF) (16). VEGF disrupts EC junctions
nd disrupts vascular smooth muscle cell function by
nhibiting PDGF-induced pericyte coverage of nas-
ent vascular sprouts (17,18). Placental-like growth
actor (PlGF) also stimulates vascular permeability,
nd its expression has been associated with plaque
ulnerability (19). The Tie receptors, Tie1 and Tie2,
nd 2 ligands for Tie2, Ang1 and Ang2, are also
ritical for vessel formation and maturation. Sources of
ng1 and Ang2 are mural cells and ECs, respectively.
ng1 is known to stabilize nascent vessels and make
hem leak resistant, presumably by facilitating com-
unication between ECs and mural cells. However,
he mechanism of vessel maturation by Ang1 is far
rom clear. The role of Ang2 appears to be contextual.
n the absence of VEGF, Ang2 acts as an antagonist
f Ang1 and destabilizes vessels, ultimately leading to
essel regression. In the presence of VEGF, Ang2
acilitates vascular sprouting. A high Ang2/Ang1 ratio
as been found in vulnerable neovascularized plaques
20). Other molecules and growth factors have also
een shown to play a role in vessel maturation.
Another avenue of interest raised by the present
tudy is whether or not it might be possible to prevent,
estroy, or “normalize” neovessels within plaques.
his topic has many parallels in other fields of
edicine, especially oncology. Given the dependence
f tumor growth and metastasis on blood vessels,
nhibition of new vessel formation or destruction of
xisting vessels of tumors has been one of the most
xciting areas of cancer research for the past decade.
ost of the clinical trials to date have tested agents
hat neutralize VEGF or inhibit its signaling.
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43We have recently proposed—and demonstrated
oth pre-clinically and clinically—that antiangiogenic
gents can prune and “normalize” the abnormal
asculature of tumors (Fig. 1) (21). Based on
imilarities to the structure and function of tumor
essels, could the judicious application of antiangio-
enic agents prune and normalize immature in-
raplaque VV, thereby preventing intraplaque hem-
rrhage (22)?
The successes of anti-VEGF strategies in cancer
iology raise the intriguing question of whether such
herapy may be applicable to atherosclerosis. How-
ver, this strategy may hold more potential pitfalls
han promises given the increased risks of athero-
hrombotic events seen with systemic antiangiogenic
herapies and the reliance of coronary collateral for-
ation on similar angiogenic pathways. Newer agents
hat might normalize abnormal vasculature without
Figure 1. Normalization Hypothesis
(A, top and bottom) In normal tissue, the effect of pro-angiogenic
growth factor, interleukin-8) is balanced by that of antiangiogenic m
normal tissues have normal structure and function. (B) When this b
are abnormal structurally and functionally, often leading to hypoxia
(e.g., cancer, atherosclerosis, macular degeneration). (C) Our hypoth
can “normalize” abnormal vessels and make them less leaky, resem
agents may be able to completely destroy these abnormal vessels,
“Janus” effect is one reason we propose to use lower doses of antia
inhibit angiogenesis. Reprinted with permission from the AAAS (Jainffecting healthy vessels such as anti-PlGF antibodies are currently being developed and may be a more
enable strategy (23,24).
In conclusion, the work of Gössl et al. (10) lends
urther insights into the association of neovasculariza-
ion and hemorrhage with coronary atherosclerosis.
urther work needs to be done to understand the
ausal relationship between hemorrhage and plaque
alcification. Until the regulatory molecular mecha-
isms of intraplaque microvessel formation are better
nderstood, we cannot be sure that the 2 are related or
ust coincidental bystanders. These and other recent
ata suggest that strategies to “normalize” intraplaque
eovessels to prevent hemorrhage may be promising
ew avenues for the prevention of coronary events.
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ecules (e.g., vascular endothelial growth factor, basic ﬁbroblast
cules (e.g., thrombospondin-1 and -2). Therefore, blood vessels in
ce tips in favor of pro-angiogenic molecules, the resulting vessels
re than 70 diseases are characterized by abnormal vasculature
is that judicious administration of effective antiangiogenic agents
normal vasculature. (D) Higher doses of potent antiangiogenic
they may also harm the vasculature of some normal tissues. This
ogenic agents rather than higher doses that can completely
al. [21]).mol
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